Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease - Wikidata - wikimedia - TriplyDB

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

http://www.wikidata.org/entity/Q34043950

about

Neuroprotective effect of Nrf2/ARE activators, CDDO ethylamide and CDDO trifluoroethylamide, in a mouse model of amyotrophic lateral sclerosis New synthetic triterpenoids: potent agents for prevention and treatment of tissue injury caused by inflammatory and oxidative stress A review on mitochondrial restorative mechanism of antioxidants in Alzheimer's disease and other neurological conditions An Overview of Potential Targets for Treating Amyotrophic Lateral Sclerosis and Huntington's Disease The Nrf2-ARE pathway: a valuable therapeutic target for the treatment of neurodegenerative diseases Mouse models of polyglutamine diseases: review and data table. Part I PGC-1α, mitochondrial dysfunction, and Huntington's disease Mouse models of polyglutamine diseases in therapeutic approaches: review and data table. Part II.Impaired mitochondrial dynamics and Nrf2 signaling contribute to compromised responses to oxidative stress in striatal cells expressing full-length mutant huntingtin Role of oxidative DNA damage in mitochondrial dysfunction and Huntington's disease pathogenesis Triterpenoid modulation of IL-17 and Nrf-2 expression ameliorates neuroinflammation and promotes remyelination in autoimmune encephalomyelitis Emerging roles of Nrf2 and phase II antioxidant enzymes in neuroprotection NRF2-regulation in brain health and disease: implication of cerebral inflammation Neuroprotective effect of caffeic acid phenethyl ester in 3-nitropropionic acid-induced striatal neurotoxicity Deficits in bioenergetics and impaired immune response in granulocytes from children with autism skn-1 is required for interneuron sensory integration and foraging behavior in Caenorhabditis elegans.Methylene blue upregulates Nrf2/ARE genes and prevents tau-related neurotoxicity Efficacy of fumaric acid esters in the R6/2 and YAC128 models of Huntington's disease.Development of Neh2-luciferase reporter and its application for high throughput screening and real-time monitoring of Nrf2 activators.Proteomic analysis shows synthetic oleanane triterpenoid binds to mTOR NRF2, cancer and calorie restriction An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1 Autophagy of mitochondria: a promising therapeutic target for neurodegenerative disease.NRF2 and cancer: the good, the bad and the importance of context.Oleanolic Acid enhances the beneficial effects of preconditioning on PC12 cells.Neuroprotective strategies involving ROS in Alzheimer disease.Pharmacologic activation of mitochondrial biogenesis exerts widespread beneficial effects in a transgenic mouse model of Huntington's disease Cancer Cell Growth Is Differentially Affected by Constitutive Activation of NRF2 by KEAP1 Deletion and Pharmacological Activation of NRF2 by the Synthetic Triterpenoid, RTA 405.Bardoxolone Methyl Prevents Fat Deposition and Inflammation in Brown Adipose Tissue and Enhances Sympathetic Activity in Mice Fed a High-Fat Diet A novel synthetic isothiocyanate ITC-57 displays antioxidant, anti-inflammatory, and neuroprotective properties in a mouse Parkinson's disease model.Nrf2/ARE Signaling Pathway: Key Mediator in Oxidative Stress and Potential Therapeutic Target in ALS Synthetic oleanane triterpenoids: multifunctional drugs with a broad range of applications for prevention and treatment of chronic disease.Targeting of Nrf2 induces DNA damage signaling and protects colonic epithelial cells from ionizing radiation.Nrf2--a therapeutic target for the treatment of neurodegenerative diseases.Target- and mechanism-based therapeutics for neurodegenerative diseases: strength in numbers Targeting nrf2-mediated gene transcription by triterpenoids and their derivatives.Enhanced mitochondrial biogenesis ameliorates disease phenotype in a full-length mouse model of Huntington's disease.Lack of association between nuclear factor erythroid-derived 2-like 2 promoter gene polymorphisms and oxidative stress biomarkers in amyotrophic lateral sclerosis patients.Oxidative Stress and Huntington's Disease: The Good, The Bad, and The Ugly.The cytoprotective role of the Keap1-Nrf2 pathway.

P2860

Q24623266-1478D1A2-B372-4998-8D21-48EA2F4EA2A1 Q24632281-089C8E9F-C59D-4095-B646-B4B575B88003 Q26781560-EFFD4A3C-32C9-4739-A9E7-04AA85378373 Q26796027-B5DF290E-792C-4CE1-9729-AAC2101C0338 Q26822972-DD2E207C-58BC-4BB8-B185-30322E4AAFCE Q26853025-4C9611AE-DA57-4987-B314-615905B701D4 Q27001671-E2CA810D-A773-457D-AFC9-8CB10FC1FDB8 Q27005950-20487F12-9AE5-4BC5-9D05-36A363D855CD Q27312215-3B78A07A-0C65-4111-8457-24BE5A5E0B7A Q28386202-9B9E6DCF-BD55-45D8-B7AF-56868343DD4F Q28394921-7A194B4E-D1D7-482B-996E-8F986A2D1573 Q28396785-94C01505-AA25-4E02-88F6-73E2C6F238CF Q28397785-9B817423-99B1-4381-A694-203CEFBC62A0 Q28833281-9F588117-1501-47F4-9B15-7577517EAF4C Q33551727-517EBC9F-D91F-4D50-BDA7-2CB9D9CD286A Q33620956-7B5C4FA0-A2C8-4A49-90DE-4A95B307104F Q33784466-D6F24909-6F2C-4757-8FD3-41CF689D7D4C Q33812932-F63151E3-5B13-42D8-91CE-979FC647F7EF Q33941688-0E50DBAB-857F-4405-8557-4E4EBF9287A3 Q33983503-BA4787DB-8DBF-413A-B0B4-12769B777B0D Q34148599-A7078583-EBA0-4A30-B16B-1E1B9F06BB3D Q34231986-09D7AB5D-A8F8-4AB6-A635-C5ACFB6D2AFD Q34287719-8A9BF199-DB5D-4BB5-BFF6-558ABA9EA476 Q34289003-84E72DF8-40A7-44FC-97A0-BE2F78371812 Q34590562-129BC7A9-F3B7-471A-A80C-E4C79921E4A0 Q34757939-D6E4BAB9-559E-4F8B-903F-5810CA88B769 Q35750228-292FDAD0-B641-4F4A-869F-BD9CB949B613 Q35753567-84B9FF26-7EE1-4E6A-85FE-4EF4A00A591B Q35808984-DFA3B488-1AF1-4F02-BE9D-18A456E64BDF Q36123780-71CF5084-94F3-4F7B-AD1C-7CBEFDB117BC Q36288479-A501D87F-EA66-4A56-AC74-B84E13A042A4 Q36293645-D2A3EF3C-5221-41C6-B83C-3C81D101A7A7 Q36378414-C19C4F95-C0CA-4463-8F42-24A55F65E86F Q36732766-277F04A8-9D3F-4B52-9603-43CED7ED5515 Q36799584-7307B0D5-3285-48FE-8125-08108CC48542 Q37145435-C84D4D45-9B40-4144-8D19-E2B445357F11 Q37368003-3F3F9D62-1D20-4B57-9973-D4AAFDD0AB01 Q37615036-EDC3CD92-B1E4-434B-A4F2-089157D86AAD Q37643688-EC71E62C-5D36-41F2-AC60-26DCE15B5184 Q37848718-220D3991-9D83-4765-B4FF-2DF8B872655A

P2860

Triterpenoids CDDO-ethyl amide and CDDO-trifluoroethyl amide improve the behavioral phenotype and brain pathology in a transgenic mouse model of Huntington's disease

http://www.wikidata.org/entity/Q34043950

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@ast

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@en

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@nl

type

label

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@ast

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@en

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@nl

prefLabel

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@ast

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@en

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@nl

P1433

Q34043950-6957709D-2F17-46A3-B083-687A9A8E1EA7

P1476

Q34043950-3857A9AD-1653-418F-AA97-CBCA7C6A3BD7

P2093

Q34043950-0C921392-438A-45E2-A4B7-812AAB11D6ED

Q34043950-4F5A65D1-CC10-4542-B6A8-0E14F52C3347

Q34043950-71297654-0596-4D56-9624-D2E8FFF13B74

Q34043950-7388CB9B-BFEE-4CB4-9493-F245F054B8A1

Q34043950-813D0996-0B34-40C7-903C-E73E9A663A1F

Q34043950-BCE24948-8F31-4982-B19B-B08150E213FC

Q34043950-C22F23DF-1988-4C09-97DD-D41324E9D6F2

Q34043950-CB61BE69-C098-4141-9FB3-E7980AF1E7FA

P2860

Q34043950-02C2F4F4-2105-4A95-B784-8C5259DEF906

Q34043950-02EB229A-20C0-4854-88FF-9B60410B7D79

Q34043950-0548F0F9-5764-4A7E-A2A0-408B65BC7593

Q34043950-05DEB59D-886F-4A68-8F71-D4FADCC61F3E

Q34043950-0676C5ED-24DF-4834-A922-3DDCF808BDDF

Q34043950-07C6FF8F-41A1-4F90-BA90-DEC4728AFD4B

Q34043950-09C71C32-066D-4E38-9D2E-82225E8F5AC7

Q34043950-0C89ECBD-9435-42C2-9234-8917E11F19D2

Q34043950-105A8DF6-0E1D-4349-AC76-40B4367C1AD7

Q34043950-126F0275-81E5-40B0-8D29-B2B75C261989

P304

Q34043950-4965CFA2-03BA-46E2-B82F-60919CA0095E

P31

Q34043950-7D12480B-2FE8-4782-8C0C-873E675EF040

P356

Q34043950-94367406-BE4A-4859-8CA1-9A988AADEE3B

P433

Q34043950-43820D1E-9664-45FC-AA59-B119E57C32C9

P478

Q34043950-CAAB1A41-CB8A-4248-8703-BBD832648710

P50

Q34043950-FE908A8D-A95C-43D8-ABF4-02649A7F7E48

P577

Q34043950-5ADE403A-F8BC-4A0B-A39F-CDB1399F0E25

P5875

Q34043950-A3490B2B-D0EA-4807-8B4F-03411CDFBE05

P698

Q34043950-D4E7DACD-2D81-4B41-BD22-1FC68FE77E2D

P921

Q34043950-6543DC00-4FF5-41DD-AAF2-38261FB62743

Q34043950-b013baee-20c0-40e9-8089-296eb5a37f9e

P932

Q34043950-B5227194-4587-44D3-803B-82EF9628C7F7

P356

J.FREERADBIOMED.2010.03.017

P1433

Free Radical Biology and Medicine

P1476

Triterpenoids CDDO-ethyl amide ...... model of Huntington's disease

@en

P2093

Charlotte Williams

http://www.w3.org/2001/XMLSchema#string

Cliona Stack

http://www.w3.org/2001/XMLSchema#string

Daniel Ho

http://www.w3.org/2001/XMLSchema#string

Elizabeth Wille

http://www.w3.org/2001/XMLSchema#string

M Flint Beal

http://www.w3.org/2001/XMLSchema#string

Magali Dumont

http://www.w3.org/2001/XMLSchema#string

Michael Sporn

http://www.w3.org/2001/XMLSchema#string

Noel Y Calingasan

http://www.w3.org/2001/XMLSchema#string

P2860

DJ-1, a cancer- and Parkinson's disease-associated protein, stabilizes the antioxidant transcriptional master regulator Nrf2

Extremely potent triterpenoid inducers of the phase 2 response: correlations of protection against oxidant and inflammatory stress

Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin

The Nrf2-ARE pathway: an indicator and modulator of oxidative stress in neurodegeneration

Mitochondrial dysfunction and oxidative stress in neurodegenerative diseases

Heme oxygenase-1/carbon monoxide: from basic science to therapeutic applications

Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice

Oxidative and electrophilic stresses activate Nrf2 through inhibition of ubiquitination activity of Keap1

Triterpenoid CDDO-methylamide improves memory and decreases amyloid plaques in a transgenic mouse model of Alzheimer's disease.

Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription.

P304

147-158

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.FREERADBIOMED.2010.03.017

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

49

http://www.w3.org/2001/XMLSchema#string

P50

P577

2010-03-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42588360

http://www.w3.org/2001/XMLSchema#string

P698

20338236

http://www.w3.org/2001/XMLSchema#string

P921

Huntington disease

P932

2916021

http://www.w3.org/2001/XMLSchema#string